TREMs in Alzheimer's disease: Genetic and clinical investigations

Jia Cheng, Xiao Feng Guo, Tian Zhang, Li Zhong, Guo Jun Bu, Xiao Fen Chen

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Triggering receptor expressed on myeloid cells (TREMs) receptors constitute a family modulators in human innate immunity system that encode by a gene cluster. Rare variants in TREM2 were reported to be associated with significant Alzheimer's disease (AD) risk. However, inconsistent results were also reported in some studies of Non-European descents. Recently, the other TREM family members are also considered to involve in AD and cerebrospinal fluid (CSF) soluble form of TREM2 (sTREM2) levels has also been associated with respond to progression of disease. In this review, we converged the data of genetic and clinical investigations to identify the clearer role of TREMs in AD. Here, comprehensively analyze of multidisciplinary fields highlights the contribution of TREMs locus to AD development.

Original languageEnglish (US)
Pages (from-to)88-95
Number of pages8
JournalClinica Chimica Acta
StatePublished - Dec 1 2016


  • Alzheimer's disease
  • Biomarker
  • Epigenetic
  • TREM2
  • sTREM2

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'TREMs in Alzheimer's disease: Genetic and clinical investigations'. Together they form a unique fingerprint.

Cite this